Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
复制标题
DOI：
10.1684/ecn.2020.0451
复制
发表时间：
2020-09-01
影响因子：
2.8
通讯作者：
Rezaei N
中科院分区：
文献类型：
--
作者：
Moradian N;Gouravani M;Salehi MA;Heidari A;Shafeghat M;Hamblin MR;Rezaei N
冠状病毒病（COVID-19）于二零二零年初达到大流行程度，并继续成为全球关注的问题。终末器官损伤和急性呼吸窘迫综合征是导致重症或危重症患者死亡的主要原因。与轻度受累患者相比，重度患者中细胞因子水平升高表明细胞因子释放综合征（CRS）发生在疾病的重度形式中。在本文中，促炎细胞因子，包括IL-1，IL-6和TNF-α的重要作用，以及它们在CRS级联反应中的作用机制进行了解释。还讨论了涉及抗IL-6和抗TNF-α抗体的潜在治疗方法，以对抗COVID-19并降低严重病例的死亡率。
Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed.
登录
查看更多内容
影响因子：
8.7
作者：
Dinarello CA
通讯作者：
Dinarello CA
影响因子：
27.4
作者：
Arima, K;Origuchi, T;Eguchi, K
通讯作者：
Eguchi, K
影响因子：
9
作者：
Channappanavar R;Perlman S
通讯作者：
Perlman S
影响因子：
24.3
作者：
Guan, Wei-jie;Liang, Wen-hua;He, Jian-xing
通讯作者：
He, Jian-xing
影响因子：
64.5
作者：
HIBI, M;MURAKAMI, M;KISHIMOTO, T
通讯作者：
KISHIMOTO, T